GlassScriptPhysician profile
Vishnu Parvathareddy
NPI 1073530549
$3,721.59
in general payments reported to CMS, 2019-2025
18 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $506 · 2022: $387 · 2023: $442 · 2024: $912 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $621.51 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $475.19 | 2021-2022 | |
| Amgen INC. | $312.39 | 2022-2024 | Aranesp, Parsabiv, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $256.73 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $237.81 | 2021 | |
| Travere Therapeutics, INC. | $226.95 | 2024-2025 | Filspari |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $226.80 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $217.97 | 2024-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $201.58 | 2024-2025 | Lokelma |
| Mallinckrodt Hospital Products INC. | $145.50 | 2025 | Terlivaz |
| Cormedix INC. | $125.12 | 2025 | |
| Horizon Therapeutics Plc | $125.00 | 2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $124.47 | 2024 | Velphoro |
| Akebia Therapeutics INC | $107.14 | 2025 | Vafseo |
| Baxter Healthcare | $98.66 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $76.41 | 2025 | Renal - Pd |
| Glaxosmithkline, LLC. | $72.75 | 2023 | Benlysta |
| Vifor Pharma, INC. | $69.61 | 2021-2024 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishnu Parvathareddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.